NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
92.99
-0.18 (-0.19%)
At close: 4:02PM EDT

92.99 0.00 (0.00%)
After hours: 4:50PM EDT

Stock chart is not supported by your current browser
Previous Close93.17
Open93.63
Bid92.93 x 3100
Ask92.94 x 1300
Day's Range92.89 - 93.69
52 Week Range72.30 - 93.69
Volume2,510,421
Avg. Volume2,054,188
Market Cap215.551B
Beta (3Y Monthly)0.64
PE Ratio (TTM)17.28
EPS (TTM)5.38
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2018-03-06
1y Target Est104.00
Trade prices are not sourced from all markets
  • Tilray Earnings Impressive: More Reasons to Buy Marijuana ETFs
    Zacks10 hours ago

    Tilray Earnings Impressive: More Reasons to Buy Marijuana ETFs

    Tilray earnings results speak of bullishness, making things better for marijuana ETF investors.

  • 3 Blue-Chip Stocks That Just Hit 52-Week Highs: Are They Buys?
    Motley Fool16 hours ago

    3 Blue-Chip Stocks That Just Hit 52-Week Highs: Are They Buys?

    Two medical-device makers and one big drugmaker are on a roll. But can their momentum continue?

  • Tilray Inc (TLRY) Q4 2018 Earnings Conference Call Transcript
    Motley Fool20 hours ago

    Tilray Inc (TLRY) Q4 2018 Earnings Conference Call Transcript

    TLRY earnings call for the period ending December 31, 2018.

  • Alnylam's (ALNY) Impressive Pipeline Drives Share Price
    Zacksyesterday

    Alnylam's (ALNY) Impressive Pipeline Drives Share Price

    Alnylam's (ALNY) share price increases on robust performance of pipeline candidates.

  • Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
    Zacksyesterday

    Novartis' (NVS) Alcon Acquired PowerVision for $285 Million

    Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.

  • Roche Gets Approval for Label Expansion of MabThera in Europe
    Zacks4 days ago

    Roche Gets Approval for Label Expansion of MabThera in Europe

    Roche (RHHBY) gets EC approval for the label expansion of its legacy RA drug, MabThera for pemphigus vulgaris.

  • Benzinga5 days ago

    The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 14) Novartis AG (NYSE: NVS ) (announced resignation of ...

  • Roche Receives EC Approval for Label Expansion of Hemlibra
    Zacks5 days ago

    Roche Receives EC Approval for Label Expansion of Hemlibra

    Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.

  • Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades
    Investopedia6 days ago

    Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades

    Shares of major drug makers including Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Amgen Inc. (AMGN), Novartis AG (NVS) and AbbVie Inc. (ABBV), are already dramatically lagging the broader market this year.

  • Novartis generics boss quits amid conjecture over business's future
    Reuters6 days ago

    Novartis generics boss quits amid conjecture over business's future

    Novartis's generics chief is quitting after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale. Richard Francis, Sandoz's boss since 2014, is stepping down, Novartis Chief Executive Vas Narasimhan said on Thursday, adding "Richard has decided that for personal reasons he cannot commit to stay with Sandoz until the transformation is completed". Francesco Balestrieri, head of Sandoz's Europe region, will become interim CEO to oversee what Narasimhan called "a multi-year transformation program" in which Sandoz re-focuses on biosimilars -- copies of patent-expired biological drugs made by rivals -- and hard-to-make generics like insulin.

  • Financial Times6 days ago

    [$$] Head of Novartis generic drugs business steps down

    The head of Novartis’s generic drugs business, Sandoz, has stepped down, sparking fresh speculation about its future. Vas Narasimhan, chief executive of the Swiss drugmaker, said that Richard Francis, who has run Sandoz for the past five years, had “decided that for personal reasons he cannot commit to stay with Sandoz” for the duration of “a multiyear transformation programme”. Mr Francis’ departure will revive speculation that Mr Narasimhan, who has sought to focus the company on its higher margin innovative medicines business since taking charge last year, is eyeing a potential spin-off of Sandoz.

  • The Wall Street Journal7 days ago

    [$$] Novartis, Volkswagen Focus on Improving Culture Following Compliance Setbacks

    The chief compliance officer, once responsible for simply making sure companies stayed within legal bounds, is now responsible for a broader range of priorities. Among them: guarding a company’s reputation, ensuring investors and government agencies have the information they need, and strengthening internal culture around compliance efforts, executives said Tuesday during a panel discussion hosted by Dow Jones Risk & Compliance and The Wall Street Journal.

  • How This Looming Patent Battle Could Challenge Bristol-Celgene Deal
    Investor's Business Daily7 days ago

    How This Looming Patent Battle Could Challenge Bristol-Celgene Deal

    Celgene and Novartis could go head-to-head in a patent battle over multiple sclerosis treatment ozanimod, an analyst said Tuesday. Novartis has a key patent for the S1P modulator drug class.

  • Allergan Announces FDA Acceptance of Migraine Candidate NDA
    Zacks7 days ago

    Allergan Announces FDA Acceptance of Migraine Candidate NDA

    Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.

  • Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer
    Zacks8 days ago

    Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer

    Roche (RHHBY) gets FDA approval for immuno-oncology drug, Tecentriq in combination with Abraxane for the treatment of breast cancer.

  • Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus
    Zacks8 days ago

    Conatus' (CNAT) Q4 Earnings Top Estimates, Emricasan in Focus

    Conatus (CNAT) makes an improvement with narrower-than-expected loss in the fourth quarter of 2018. Also, revenues beat mark.

  • 10 Stocks For The Gene Therapy Revolution
    Investopedia9 days ago

    10 Stocks For The Gene Therapy Revolution

    Gene therapy, which treats genetic diseases by replacing faulty genes, is a rapidly growing field, with merger activity on the rise.

  • Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
    Zacks11 days ago

    Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy

    Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.

  • How Novartis Is Transforming Its Structure in 2019
    Market Realist12 days ago

    How Novartis Is Transforming Its Structure in 2019

    How Novartis and Bristol-Myers Squibb Stack Up(Continued from Prior Part)Business transformation Since fiscal 2018, Novartis (NVS) has been focused on transforming itself into a new focused medicines company. According to the company’s

  • Dutch join backlash at expensive drugs by making their own
    Reuters12 days ago

    Dutch join backlash at expensive drugs by making their own

    In a radiation-proof room at the Erasmus Medical Center in Rotterdam, Emar Thomasa sits behind shielded glass as he carefully measures and mixes lutetium octreotate, an intravenous treatment for certain types of cancer. Drug firm Novartis, which in 2018 acquired rights to sell it in Europe, is asking more than five times that for its proprietary version, Lutathera. Thomasa is part of a protest against high drug prices launched by an unlikely group of rebels: Dutch pharmacies.

  • BMY and NVS: How Tax Rates and Interest Expenses Stack Up
    Market Realist12 days ago

    BMY and NVS: How Tax Rates and Interest Expenses Stack Up

    How Novartis and Bristol-Myers Squibb Stack Up(Continued from Prior Part)Tax rate projectionsIn fiscal 2018, Novartis (NVS) and Bristol-Myers Squibb (BMY) reported an effective tax rate of 17.05% and 9.28%, respectively. In its fourth-quarter

  • How Novartis and BMY’s Dividend Profiles Stack Up
    Market Realist13 days ago

    How Novartis and BMY’s Dividend Profiles Stack Up

    How Novartis and Bristol-Myers Squibb Stack Up(Continued from Prior Part)Dividend guidance In fiscal 2018, Novartis (NVS) and Bristol-Myers Squibb (BMY) reported an annual dividend per share of $2.85 and $1.60, respectively. According to

  • Alnylam Stock Down Despite Positive Phase III Givosiran Data
    Zacks13 days ago

    Alnylam Stock Down Despite Positive Phase III Givosiran Data

    Alnylam (ALNY) reports positive phase III data on investigational candidate, givosiran. Despite the results, its shares slipped almost 4% on investors' concern regarding adverse events.

  • Novartis or BMY: Who’s Controlling Expenses Better?
    Market Realist13 days ago

    Novartis or BMY: Who’s Controlling Expenses Better?

    How Novartis and Bristol-Myers Squibb Stack Up(Continued from Prior Part)Expenses guidance for fiscal 2019 In its fourth-quarter earnings investor presentation, Novartis (NVS) has guided for core net financial expenses for its new structure, which